Clene plans accelerated FDA filing for ALS drug CNM-Au8 in Q3 2026
Clene Inc. (NASDAQ: CLNN) announced that the Food and Drug Administration stated the company's proposed data may support submission of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
